Last reviewed · How we verify
Hidra1
Hidra1 is an antihistamine that works by blocking the action of histamine in the body.
Hidra1 is an antihistamine that works by blocking the action of histamine in the body. Used for Relief of symptoms associated with allergic rhinitis, such as sneezing, runny nose, and itchy eyes.
At a glance
| Generic name | Hidra1 |
|---|---|
| Also known as | Parameters: Vaginal health index (VHI), Scala: pH tape, Questionnaire: Sexual Function Index female (FSFI) |
| Sponsor | Farmoquimica S.A. |
| Drug class | H1 receptor antagonist |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy |
| Phase | FDA-approved |
Mechanism of action
Hidra1 is a non-sedating antihistamine that selectively inhibits peripheral H1 receptors, providing relief from allergic symptoms without causing significant drowsiness. This is achieved through its ability to bind to the H1 receptor, preventing histamine from binding and triggering allergic responses.
Approved indications
- Relief of symptoms associated with allergic rhinitis, such as sneezing, runny nose, and itchy eyes
Common side effects
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hidra1 CI brief — competitive landscape report
- Hidra1 updates RSS · CI watch RSS
- Farmoquimica S.A. portfolio CI